ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
ALX Oncology has raised $10.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in June 2026.
ALX Oncology's investors include RA Capital Management, Janus Henderson Investors, Vivo Capital, Redmile Group, Foresite Capital.
ALX Oncology is headquartered in San Francisco, United States.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
ALX Oncology is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ALX Oncology — Funding & Investors." VCBacked, June 25, 2026, https://www.vcbacked.co/company/alx-oncology. Accessed November 12, 2026.
VCBacked. (2026). ALX Oncology — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/alx-oncology
{{cite web |title=ALX Oncology — Funding & Investors |url=https://www.vcbacked.co/company/alx-oncology |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at ALX Oncology? Request a listing update